+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Immune Checkpoint Inhibitor"

Stomach Cancer Treatment - Global Strategic Business Report - Product Thumbnail Image

Stomach Cancer Treatment - Global Strategic Business Report

  • Report
  • October 2025
  • 371 Pages
  • Global
From
Antibody Fragments - Global Strategic Business Report - Product Thumbnail Image

Antibody Fragments - Global Strategic Business Report

  • Report
  • October 2025
  • 176 Pages
  • Global
From
Epithelioma Treatment - Global Strategic Business Report - Product Thumbnail Image

Epithelioma Treatment - Global Strategic Business Report

  • Report
  • October 2025
  • 380 Pages
  • Global
From
Peptide Drug Conjugates - Global Strategic Business Report - Product Thumbnail Image

Peptide Drug Conjugates - Global Strategic Business Report

  • Report
  • October 2025
  • 282 Pages
  • Global
From
From
Bispecific Antibodies - Global Strategic Business Report - Product Thumbnail Image

Bispecific Antibodies - Global Strategic Business Report

  • Report
  • October 2025
  • 104 Pages
  • Global
From
Immunotoxins - Global Strategic Business Report - Product Thumbnail Image

Immunotoxins - Global Strategic Business Report

  • Report
  • October 2025
  • 377 Pages
  • Global
From
From
From
From
MEK Inhibitors - Global Strategic Business Report - Product Thumbnail Image

MEK Inhibitors - Global Strategic Business Report

  • Report
  • October 2025
  • 132 Pages
  • Global
From
Combination Antibody Therapy - Global Strategic Business Report - Product Thumbnail Image

Combination Antibody Therapy - Global Strategic Business Report

  • Report
  • October 2025
  • 196 Pages
  • Global
From
Gynecological Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Gynecological Cancer Drugs - Global Strategic Business Report

  • Report
  • October 2025
  • 193 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Thumbnail Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • October 2025
  • 224 Pages
  • Global
From
Urothelial Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Urothelial Cancer Drugs - Global Strategic Business Report

  • Report
  • October 2025
  • 126 Pages
  • Global
From
From
Immunotherapy Drugs - Global Strategic Business Report - Product Thumbnail Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • October 2025
  • 193 Pages
  • Global
From
Liver Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • October 2025
  • 277 Pages
  • Global
From
Compounding Chemotherapy Market Report 2025 - Product Thumbnail Image

Compounding Chemotherapy Market Report 2025

  • Report
  • October 2025
  • 250 Pages
  • Global
From
Gastric Cancer Therapy Market Report 2025 - Product Thumbnail Image

Gastric Cancer Therapy Market Report 2025

  • Report
  • October 2025
  • 250 Pages
  • Global
From
Loading Indicator

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more